Business Wire

CA-NETAPP

Share
With Spot Wave, NetApp Helps Organizations Drive Down Infrastructure Cost and Complexity for Big Data Applications on Kubernetes

Global cloud-led, data-centric software company, NetApp (NASDAQ: NTAP), today announced the launch of Spot Wave by NetApp, and Spot Ocean’s support of Microsoft Azure Kubernetes Service. Together, these products provide customers with leading solutions for simple, scalable and efficient infrastructure for cloud-native applications.

Wave automates the provisioning, deployment, autoscaling and optimization for running Apache Spark big data applications on Kubernetes in the cloud and helps to reduce cloud waste and costs by up to 90%. Using Wave as a turnkey product, organizations can deploy Spark environments faster and more easily, and focus on putting their data to work knowing that Wave is ensuring their infrastructure is continuously optimized for availability, performance and cost.

Wave is built on Spot’s AI-based engine, using the same proven technology as Spot Ocean. Wave provides:

  • Cost optimization: Wave runs Spark jobs on containerized infrastructure using an intelligent mix of spot, on-demand and reserved instances, affording customers up to 90% cost savings on cloud infrastructure.
  • Serverless infrastructure & Spark-aware autoscaling: Built-in autoscaling matches the right type and size of compute instances to Spark jobs based on workload requirements to maximize performance and efficiency.
  • Spark job right-sizing and monitoring: Continuously tune Spark configuration for jobs based on analysis of actual Spark job requirements.

“Organizations are rapidly adopting Kubernetes to deliver cloud-native applications with greater speed and agility, not only for stateless services but also for big data applications,” said Amiram Shachar, vice president and general manager of Spot by NetApp. “The necessity for organizations to balance cloud infrastructure cost, performance and availability for optimal efficiency is complex and time-consuming. Spot Wave and Ocean are solving that problem by providing a serverless experience for Spark and ensuring their infrastructure is continuously optimized.”

NetApp also announced that Ocean, Spot’s serverless container engine and the foundation of Spot Wave, now supports Microsoft Azure Kubernetes Service (AKS), adding to its support for AWS ECS (Elastic Container Service) and EKS (Elastic Kubernetes Service), and Google’s GKE (Google Kubernetes Engine).

“Wave builds on the capabilities that we love in Ocean, focusing on the specific needs of big data applications,” said Gal Aviv, chief technology officer at Fyber. “It will be very powerful to be able to plug Spark applications into Wave. The solution also has the amazing value of executing jobs with existing tools and potentially spin up the right infrastructure to power intensive ML applications.”

NetApp and Spot by NetApp have deep histories of involvement and experience in Kubernetes and the Kubernetes community. With ongoing investments in NetApp and Spot by NetApp products for Kubernetes, NetApp provides the leading solutions and capabilities for application-driven infrastructure and data management needed by companies to run critical cloud-native applications.

More information on Spot Wave is available online at https://spot.io/products/wave .

About NetApp

NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software, and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .

NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye